Adjuvant Chemotherapy for Triple Negative Breast Cancer Patients With Residual Disease After Neoadjuvant Chemotherapy

NCT04437160 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

286

Enrollment

OTHER

Sponsor class

Conditions

Triple Negative Breast Cancer

Interventions

DRUG: Epirubicin or Pirarubicin
DRUG: Cyclophosphamide

Sponsor

Chinese Academy of Medical Sciences